Form 4: Nuvalent CFO Alexandra Balcom Reports Stock Transactions

Alexandra Balcom, CFO of Nuvalent, Inc., reports the acquisition and disposition of Class A Common Stock and stock options on January 6, 2025.

Summary

• On January 6, 2025, Alexandra Balcom, the Chief Financial Officer of Nuvalent, Inc., engaged in transactions involving the company's Class A Common Stock and stock options.
• Balcom acquired 18,750 shares of Class A Common Stock through restricted stock units (RSUs) at $0.00 per share.
• She also sold 1,152 shares at a weighted average price of $78.28, 691 shares at $79.33, and 2,173 shares at $80.54.
• These sales were executed under a pre-arranged Rule 10b5-1 plan to cover tax obligations related to vesting equity awards.
• Additionally, Balcom acquired options to purchase 37,500 shares of Class A Common Stock at an exercise price of $78.09.
• Following these transactions, Balcom directly owns 61,734 shares of Class A Common Stock and options to purchase 37,500 shares.
• The RSUs vest in three equal annual installments following January 6, 2025, and the stock options vest in equal monthly installments over four years following the same date, contingent upon continued service to Nuvalent, Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation and tax obligations. The use of a 10b5-1 plan suggests a proactive approach to compliance.

Positives

• The acquisition of RSUs and stock options indicates continued alignment of the CFO's interests with the company's long-term performance.

Negatives

• The sale of shares, even for tax obligations, could be perceived negatively by some investors, although it was pre-planned.

Risks

• The vesting of RSUs and stock options is contingent upon continued service, creating a potential risk if the CFO were to leave the company.
• Market fluctuations could impact the value of the shares and options, affecting the CFO's personal investment portfolio.

Future Outlook

The vesting schedules for the RSUs and stock options indicate a multi-year commitment from the CFO to the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The use of a 10b5-1 plan is a common practice to avoid accusations of insider trading.

Comparison to Industry Standards

• Comparing Nuvalent's insider trading activity to similar biotech companies like Relay Therapeutics or Black Diamond Therapeutics would provide context.
• Examining the frequency and volume of insider transactions in these companies can help determine if Nuvalent's activity is typical.
• Analyzing the use of 10b5-1 plans among peer companies can also offer insights into Nuvalent's approach to managing insider trading risks.

Stakeholder Impact

• The transactions have a minor impact on shareholders, as the sales are pre-planned and intended to cover tax obligations.
• Employees may view the vesting of RSUs and stock options as a positive sign of the company's commitment to its executives.

Key Dates